Home
ARQT
ARQT News

Latest Arcutis Biotherapeutics Inc. (ARQT) News on February 22, 2025

Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Zacks

2 days ago

Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Arcutis to Present at the TD Cowen 45th Annual Health Care Conference

GlobeNewswire

4 days ago

Arcutis to Present at the TD Cowen 45th Annual Health Care Conference

Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 51.64%: Read This Before Placing a Bet

Zacks

5 days ago

Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 51.64%: Read This Before Placing a Bet

High Growth Tech Stocks To Watch In February 2025

Simply Wall St.

5 days ago

High Growth Tech Stocks To Watch In February 2025

Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates

Zacks

9 days ago

Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates

Arcutis Biotherapeutics (ARQT) Surges 15.9%: Is This an Indication of Further Gains?

Zacks

9 days ago

Arcutis Biotherapeutics (ARQT) Surges 15.9%: Is This an Indication of Further Gains?

Here's Why Arcutis Biotherapeutics (ARQT) Could be Great Choice for a Bottom Fisher

Zacks

11 days ago

Here's Why Arcutis Biotherapeutics (ARQT) Could be Great Choice for a Bottom Fisher

Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains.

Investor's Business Daily

16 days ago

Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains.

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

17 days ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Odell Beckham Jr. and Arcutis Tackle Seborrheic Dermatitis in a "Clear Win for Your Skin"

PR Newswire

18 days ago

Odell Beckham Jr. and Arcutis Tackle Seborrheic Dermatitis in a "Clear Win for Your Skin"

Are Medical Stocks Lagging Addus HomeCare (ADUS) This Year?

Zacks

25 days ago

Are Medical Stocks Lagging Addus HomeCare (ADUS) This Year?

Arcutis to Present at the Guggenheim SMID Cap Biotech Conference

GlobeNewswire

a month ago

Arcutis to Present at the Guggenheim SMID Cap Biotech Conference

Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 37.43%: Here's is How to Trade

Zacks

a month ago

Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 37.43%: Here's is How to Trade

MT Newswires

a month ago

Arcutis Biotherapeutics Expects Fiscal Q4 Revenue to Soar Driven by Zoryve Demand

Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million

GlobeNewswire

a month ago

Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million

High Growth Tech Stocks In The United States To Watch

Simply Wall St.

a month ago

High Growth Tech Stocks In The United States To Watch

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 months ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Here's Why Arcutis Stock More Than Doubled in Market Value in One Year

Zacks

2 months ago

Here's Why Arcutis Stock More Than Doubled in Market Value in One Year

MT Newswires

2 months ago

HC Wainwright Initiates Arcutis Biotherapeutics at Buy With $19 Price Target

What Awaits These 4 Biotech Stocks That More Than Doubled in 2024

Zacks

2 months ago

What Awaits These 4 Biotech Stocks That More Than Doubled in 2024

MT Newswires

2 months ago

Arcutis Biotherapeutics Submits Supplemental New Drug Application to FDA for Zoryve Cream

Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

GlobeNewswire

2 months ago

Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

3 months ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

High Growth Tech Stocks To Watch In December 2024

Simply Wall St.

3 months ago

High Growth Tech Stocks To Watch In December 2024

Argus Research

3 months ago

Daily – Vickers Top Buyers & Sellers for 12/04/2024

Arcutis Announces Promotions on Executive Management Team

GlobeNewswire

3 months ago

Arcutis Announces Promotions on Executive Management Team

Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 60.12% as Wall Street Analysts Expect?

Zacks

3 months ago

Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 60.12% as Wall Street Analysts Expect?

Arcutis Biotherapeutics, Inc. (ARQT) Now Trades Above Golden Cross: Time to Buy?

Zacks

3 months ago

Arcutis Biotherapeutics, Inc. (ARQT) Now Trades Above Golden Cross: Time to Buy?

Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 200-Day Moving Average

Zacks

3 months ago

Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 200-Day Moving Average

Arcutis Biotherapeutics, Inc. (ARQT) Crossed Above the 50-Day Moving Average: What That Means for Investors

Zacks

3 months ago

Arcutis Biotherapeutics, Inc. (ARQT) Crossed Above the 50-Day Moving Average: What That Means for Investors

Bears are Losing Control Over Arcutis Biotherapeutics (ARQT), Here's Why It's a 'Buy' Now

Zacks

3 months ago

Bears are Losing Control Over Arcutis Biotherapeutics (ARQT), Here's Why It's a 'Buy' Now

Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average

Zacks

3 months ago

Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average

Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour

GlobeNewswire

3 months ago

Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour

Wall Street Analysts See a 70.33% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High?

Zacks

3 months ago

Wall Street Analysts See a 70.33% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High?

Arcutis Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

3 months ago

Arcutis Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations

Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings Call Highlights: Robust Growth and ...

GuruFocus.com

3 months ago

Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings Call Highlights: Robust Growth and ...

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Tops Revenue Estimates

Zacks

4 months ago

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Tops Revenue Estimates

Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

4 months ago

Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update

High Growth Tech Stocks In The United States To Watch

Simply Wall St.

4 months ago

High Growth Tech Stocks In The United States To Watch

Earnings To Watch: Arcutis Biotherapeutics Inc (ARQT) Reports Q3 2024 Result

GuruFocus.com

4 months ago

Earnings To Watch: Arcutis Biotherapeutics Inc (ARQT) Reports Q3 2024 Result

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

4 months ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Zacks

4 months ago

Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Zacks

4 months ago

Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting

GlobeNewswire

4 months ago

Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting

Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference

GlobeNewswire

4 months ago

Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference

MT Newswires

4 months ago

Arcutis Biotherapeutics' Zoryve Approved to Treat Seborrheic Dermatitis in Canada

Health Canada approves Arcutis’ ZORYVE foam for seborrheic dermatitis

Pharmaceutical Technology

4 months ago

Health Canada approves Arcutis’ ZORYVE foam for seborrheic dermatitis

Arcutis Canada Announces Health Canada Approval of ZORYVE® Foam to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

CNW Group

4 months ago

Arcutis Canada Announces Health Canada Approval of ZORYVE® Foam to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

MT Newswires

4 months ago

Arcutis Biotherapeutics Receives Approval in Canada for Skin Disease Cream Zoryve

Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

GlobeNewswire

4 months ago

Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

Arcutis Biotherapeutics, Inc (ARQT): A Small-Cap Leader in Skin Disease Treatments

Insider Monkey

4 months ago

Arcutis Biotherapeutics, Inc (ARQT): A Small-Cap Leader in Skin Disease Treatments

Zoryve Drives Revenue Growth at Arcutis Biotherapeutics, Inc. (ARQT)

Insider Monkey

4 months ago

Zoryve Drives Revenue Growth at Arcutis Biotherapeutics, Inc. (ARQT)

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

5 months ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Exploring High Growth Tech Stocks In The US October 2024

Simply Wall St.

5 months ago

Exploring High Growth Tech Stocks In The US October 2024

New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types

GlobeNewswire

5 months ago

New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types

MT Newswires

5 months ago

Arcutis Biotherapeutics Says US FDA Accepts Supplemental New Drug Application for Psoriasis Treatment

FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

GlobeNewswire

5 months ago

FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

MT Newswires

5 months ago

Arcutis Biotherapeutics Says Phase 3 Data Confirm Zoryve's Efficacy in Atopic Dermatitis

Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology

GlobeNewswire

5 months ago

Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology

Insider Selling: Director Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics Inc (ARQT)

GuruFocus.com

6 months ago

Insider Selling: Director Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics Inc (ARQT)

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

6 months ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255

GlobeNewswire

6 months ago

Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255

Arcutis Biotherapeutics, Inc. (ARQT): This Small-Cap Healthcare Stock Is A Good Buy Right Now

Insider Monkey

6 months ago

Arcutis Biotherapeutics, Inc. (ARQT): This Small-Cap Healthcare Stock Is A Good Buy Right Now

GlobeNewswire

6 months ago

Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

MT Newswires

6 months ago

Jefferies Initiates Arcutis Biotherapeutics at Buy

Exploring Three High Growth Tech Stocks In The United States

Simply Wall St.

6 months ago

Exploring Three High Growth Tech Stocks In The United States

Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

GlobeNewswire

6 months ago

Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Thomson Reuters StreetEvents

6 months ago

Q2 2024 Arcutis Biotherapeutics Inc Earnings Call

CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

6 months ago

CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Misses Revenue Estimates

Zacks

6 months ago

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Misses Revenue Estimates

MT Newswires

6 months ago

Arcutis Biotherapeutics Q2 Loss Narrows, Revenue Rises

Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

6 months ago

Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update

Analysts Expect Breakeven For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Before Long

Simply Wall St.

6 months ago

Analysts Expect Breakeven For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Before Long

Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know

Zacks

6 months ago

Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

7 months ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024

GlobeNewswire

7 months ago

Arcutis to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024

Guardant Health (GH) Moves 6.9% Higher: Will This Strength Last?

Zacks

7 months ago

Guardant Health (GH) Moves 6.9% Higher: Will This Strength Last?

MT Newswires

7 months ago

Arcutis Biotherapeutics Signs Co-Promote Deal for Zoryve With Kowa Pharmaceuticals; Shares Down

Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.

GlobeNewswire

7 months ago

Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.

Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis

GlobeNewswire

7 months ago

Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis

MT Newswires

7 months ago

Arcutis Biotherapeutics Submits Supplemental New Drug Application to US FDA for Psoriasis Treatment

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

GlobeNewswire

7 months ago

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL

GlobeNewswire

7 months ago

Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL

Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?

Zacks

7 months ago

Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?

Arcutis (ARQT) Stock Rises 31% in the Past Month: Here's Why

Zacks

7 months ago

Arcutis (ARQT) Stock Rises 31% in the Past Month: Here's Why

Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data

Zacks

7 months ago

Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data

Immutep (IMMP) Up as Combo Therapy Meets Carcinoma Study Goals

Zacks

7 months ago

Immutep (IMMP) Up as Combo Therapy Meets Carcinoma Study Goals

Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why

Zacks

7 months ago

Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why

Pacira (PCRX) Rises on Proposed Exparel Reimbursement Plan

Zacks

7 months ago

Pacira (PCRX) Rises on Proposed Exparel Reimbursement Plan

Inovio (INO) Up as Lead Drug Gets Innovative Medicine Tag in UK

Zacks

7 months ago

Inovio (INO) Up as Lead Drug Gets Innovative Medicine Tag in UK

Arcutis bags FDA approval for atopic dermatitis cream after delay

Pharmaceutical Technology

7 months ago

Arcutis bags FDA approval for atopic dermatitis cream after delay

Indivior (INDV) Down on Dropping Schizophrenia Drug, Cuts '24 View

Zacks

7 months ago

Indivior (INDV) Down on Dropping Schizophrenia Drug, Cuts '24 View

FDA Approves Expanded Use Of Arcutis Biotherapeutics' Eczema Drug For Patients As Young As 6 Years

Benzinga

7 months ago

FDA Approves Expanded Use Of Arcutis Biotherapeutics' Eczema Drug For Patients As Young As 6 Years

AbbVie names new R&D head; Arcutis eczema cream approved

BioPharma Dive

7 months ago

AbbVie names new R&D head; Arcutis eczema cream approved

MT Newswires

7 months ago

Arcutis Biotherapeutics' Zoryve Gets US FDA Approval for Atopic Dermatitis

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age

GlobeNewswire

7 months ago

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age

Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis

GlobeNewswire

7 months ago

Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

8 months ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Investor's Business Daily

8 months ago

Cheap Stocks To Buy: This Microcap Gold Stock Breaks Out

FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease

Zacks

8 months ago

FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease

Share on Social Networks: